Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

NCT01182675 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Insufficient evidence of efficacy

Conditions

Severe Combined Immunodeficiency

Interventions

DRUG: Transplant Conditioning with Mobilization Only
DRUG: Transplant Conditioning with Mobilization and Alemtuzumab

Sponsor

University of California, San Francisco